AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer

CAR-T Digest - August 2020

29 Apr 2024: AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer

AstraZeneca and Daiichi Sankyo’s drug Enhertu shows effectiveness against HR+ metastatic breast cancer with low HER2 expression
Enhertu showed superior efficacy over standard chemotherapy in delaying tumor progression or death in the Phase 3 trial DESTINY-Breast06 trial.
Enhertu could establish a new SOC for patients with HER2-low and HER2-ultralow metastatic breast cancer after one or more lines of endocrine therapy
This becomes significant as roughly 60% to 65% of HR+, HER2- BC is classified as HER2-low, with another 25% potentially falling into the HER2-ultralow category
Enhertu received a tumor-agnostic FDA approval for previously treated HER2+ solid tumors